Literature DB >> 15245797

Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neurons.

Wang-Ping Hu1, Xing-Hong You, Bing-Cai Guan, Li-Qiang Ru, Jian-Guo Chen, Zhi-Wang Li.   

Abstract

The present study aimed to investigate the interaction between the coexistent SP receptor and 5-HT3 receptor in trigeminal ganglion (TG) neurons using whole-cell patch clamp technique. The majority of the neurons examined responded to 5-HT with an inward current (I5-HT) (78.2%, 79/101) that could be blocked by 5-HT3 receptor antagonist, ICS-205,930. The I5-HT was potentiated by preapplication of SP (10(-10) to 10(-8) M) in most 5-HT-sensitive cells(78.5%, 62/79). Coapplication of SP and GR-82334, antagonist of NK1 receptor, had no enhancing effect on I5-HT. The concentration-response curves for 5-HT with and without SP preapplication show that: (1) the threshold 5-HT concentrations with and without SP preapplication are basically the same, while SP preapplication increased the maximal value of I5-HT by 38.0% of its control; (2) the EC50 values of the curves with and without SP pretreatment are very close, i.e. 1.89 x 10(-5) M and 2.08 x 10(-5) M (P > 0.1; n = 9), respectively. Intracellular dialysis of GDP-beta-S, a non-hydrolyzable GDP analog, and GF-109203X, a selective protein kinase C inhibitor, removed the SP potentiation of I5-HT. These results may offer a clue to understanding the mechanism underlying the generation and/or regulation of peripheral pain caused by tissue damage inflammation, etc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15245797     DOI: 10.1016/j.neulet.2004.04.072

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.

Authors:  Camilo Rojas; Ying Li; Jie Zhang; Marigo Stathis; Jesse Alt; Ajit G Thomas; Sergio Cantoreggi; Silvia Sebastiani; Claudio Pietra; Barbara S Slusher
Journal:  J Pharmacol Exp Ther       Date:  2010-08-19       Impact factor: 4.030

2.  Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Flavia Longo; Giovanni Mansueto; Vittoria Lapadula; Rita De Sanctis; Silvia Quadrini; Roberta Grande; Bruno Gori; Amelia Altavilla; I D'Antoni; Ester Del Signore; Luciano Stumbo; Cristina De Luca; Barbara Cimadon; Enrico Cortesi; Teresa Gamucci; Marisa Di Seri
Journal:  Support Care Cancer       Date:  2010-06-16       Impact factor: 3.603

3.  2',3'-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents.

Authors:  Diego Dal Ben; Anna Marchenkova; Ajiroghene Thomas; Catia Lambertucci; Andrea Spinaci; Gabriella Marucci; Andrea Nistri; Rosaria Volpini
Journal:  Purinergic Signal       Date:  2016-10-18       Impact factor: 3.765

Review 4.  Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.

Authors:  Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow
Journal:  Expert Opin Pharmacother       Date:  2013-04       Impact factor: 3.889

5.  Involvement of 5-Serotonin and Substance p Pathways in Dichroa Alkali Salt-Induced Acute Pica in Rats.

Authors:  Lina Ma; Sidi Li; Jian Li; Guangping Zhang; Hongping Hou; Zuguang Ye
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

6.  An Integrated In Silico and In Vivo Approach to Identify Protective Effects of Palonosetron in Cisplatin-Induced Nephrotoxicity.

Authors:  Eri Wakai; Yuya Suzumura; Kenji Ikemura; Toshiro Mizuno; Masatoshi Watanabe; Kazuhiko Takeuchi; Yuhei Nishimura
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-20

7.  Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells.

Authors:  Ajit G Thomas; Marigo Stathis; Camilo Rojas; Barbara S Slusher
Journal:  Exp Brain Res       Date:  2014-06-27       Impact factor: 1.972

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.